Back to Search
CLARISSA DASS, D.O.
D.O.
Cardiovascular Disease Physician
NPI: 1598175259IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine Physician
Family Medicine
Code: 207Q00000X
5101020960(MI)
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
5101020960(MI)
Education
MICHIGAN STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Class of 2014
Research & Publications (20)
Irrigant divalent cation concentrations influence bacterial adhesion.
PMID 19577252·J Surg Res·2009
7-preclinical
A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma.
PMID 19345993·Biomaterials·2009
7-preclinical
Review: doxorubicin delivery systems based on chitosan for cancer therapy.
PMID 19178759·J Pharm Pharmacol·2009
6-review
Development of chondrosarcoma animal models for assessment of adjuvant therapy.
PMID 19566512·ANZ J Surg·2009
6-review
Quantification of endogenous alpha- and gamma-endorphins in rat brain by liquid chromatography-tandem mass spectrometry.
PMID 19486879·Anal Biochem·2009
7-preclinical
Cancer, chitosan nanoparticles and catalytic nucleic acids.
PMID 19126291·J Pharm Pharmacol·2009
6-review
A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy.
PMID 19505719·Biomaterials·2009
7-preclinical
Chitosan-dibasic orthophosphate hydrogel: a potential drug delivery system.
PMID 19340925·Int J Pharm·2009
8-other
Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy.
PMID 18497564·Cancer Biol Ther·2008
7-preclinical
Elevated leptin expression in a rat model of fracture and traumatic brain injury.
PMID 19000372·J Pharm Pharmacol·2008
7-preclinical
c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model.
PMID 18708361·Mol Cancer Res·2008
7-preclinical
c-Jun knockdown sensitizes osteosarcoma to doxorubicin.
PMID 18645001·Mol Cancer Ther·2008
7-preclinical
C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies.
PMID 18604982·Pharmazie·2008
6-review
PEDF as an emerging therapeutic candidate for osteosarcoma.
PMID 19075591·Curr Cancer Drug Targets·2008
6-review
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway.
PMID 19001431·Mol Cancer Ther·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 50 N PERRY ST
PONTIAC, MI 48342 - Phone
- (248) 338-5000
Quick Facts
- NPI
- 1598175259
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile